OPKO Health is a diversified healthcare company operating in pharmaceuticals and diagnostics, with marketed products including NGENLA®, a growth hormone therapy co-developed with Pfizer; Rayaldee, a treatment for chronic kidney disease complications; and the 4Kscore® prostate cancer risk assessment test. The company generates revenue through royalties and profit-sharing arrangements on pharmaceutical sales, direct sales of diagnostic tests and specialty pharmaceutical products, and international pharmaceutical distribution operations in Spain, Ireland, Chile, and Mexico. OPKO pursues growth by advancing its pipeline of multispecific antibodies and vaccines for cancer and infectious diseases, expanding marketed products into new indications and geographies, and scaling its refocused diagnostics business while leveraging strategic partnerships with major pharmaceutical companies to reduce development costs and share commercialization resources.